Development of a SEMA3C targeted therapeutic for treatment of clear cell renal cell carcinoma, lung cancer, breast cancer and colorectal cancer

The major focus of this proposal is to perform preclinical studies to support clinical development of a novel inhibitor for treatment of different caners such as breast, lung, colorectal and kidney. We have recently developed a novel therapeutic protein that selectively inhibits multiple pathways for treatment of advanced prostate cancer.